Latest News Archive

Please select Category, Year, and then Month to display items
Years
2019 2020 2021 2024
Previous Archive
18 July 2019 | Story Julian Roup | Photo Leonie Bolleurs
Clear glass
UFS researchers Lucas Erasmus (left), researcher in the UFS Department of Physics and Prof Hendrik Swart, senior professor in the UFS Department of Physics and SARChI chair (South African Research Chairs Initiative) in Solid State Luminescent and Advanced Materials, with the equipment used for the ground-breaking research.

A revolutionary new type of window glass – in effect a transparent solar panel - is the objective of joint research being done by the University of the Free State (UFS) in South Africa and Ghent University in Belgium. 

A working model has been created which proves the viability of the process which now needs to be refined, made more efficient and brought to the market. It is hoped to achieve this within a decade.

This new product will have the capacity to revolutionise the generation of power cheaply from the sun to power homes, factories and cities in a new clean way.

Academics from the UFS, Prof Hendrik Swart and Lucas Erasmus are doing joint research with Ghent University in Belgium, to find solutions for energy production. 

The two universities entered into an agreement recently for this research into electricity generation. The research is driven by the UFS and was prompted by ever-rising electricity prices and growing demand for electricity production. South Africa lives with constant power outages which leaves people stuck in lifts and facing chaos on the roads as traffic lights cut out. Many people who can afford them now rely on generators.

Prof Hendrik Swart, senior professor in the Department of Physics at the University of the Free State and SARChI chair (South African Research Chairs Initiative) in Solid State Luminescent and Advanced Materials, says: “An innovation like this which can help to replace traditional means of carbon based fuel for power generation in our daily lives would be hugely welcome.”

Swart explains the main objective of the research: “The idea is to develop glass that is transparent to visible light, just like the glass you find in the windows of buildings, motor vehicles and mobile electronic devices. However, by incorporating the right phosphor materials inside the glass, the light from the sun that is invisible to the human eye (ultraviolet and infrared light) can be collected, converted and concentrated to the sides of the glass panel where solar panels can be mounted. 

This invisible light can then be used to generate electricity to power buildings, vehicles and electronic devices. The goal is therefore to create a type of transparent solar panel.”

Swart says this technology can be implemented in the building environment to meet the energy demands of the people inside the buildings. “The technology is also good news for the 4.7 billion cell phone users in the world, as it can be implemented in the screens of cell phones, where the sun or the ambient light of a room can be used to power the device without affecting its appearance,” he said.

Another possible application is in electric cars, where the windows can be used to help power the vehicle.

Lucas Erasmus who is working with Prof Swart adds: “We are also looking at implementing this idea into hard, durable plastics that can act as a replacement for zinc roofs. This will allow visible diffused light to enter housing and the invisible light can then be used to generate electricity. The device also concentrates the light from a large area to the small area on the sides where the solar panels are placed; therefore, reducing the number of solar panels needed and in return, reducing the cost.”

It is envisaged that the technology will take about a decade to refine and implement. This study is currently on-going, and UFS are experimenting and testing different materials in order to optimise the device in the laboratory. It then needs to be upscaled in order to test it in the field. “It is truly the technology of the future,” says 
Erasmus.

The UFS envisages that the end result of this research will provide an attractive solution to address the energy demands of buildings, electric motor vehicles and mobile electronics without affecting their appearance. 

According to Swart, the agreement entails a joint doctoral degree in which both universities will supervise the project and the awarding of the doctorate. Lucas Erasmus, a student at the UFS, has been tasked with the assignment to conduct research at both institutions.

News Archive

Nuclear Medicine on the forefront of cancer research
2017-07-10

Description: Nuclear Medicine on the forefront of cancer research Tags: Nuclear Medicine, cancer research, Dr Je’nine Horn-Lodewyk’s, tumour detection method, cancer, Department of Nuclear Medicine 

Dr Je’nine Horn-Lodewyk’s tumour detection method
could be the cost-effective breakthrough needed to decrease
the mortality rate in breast cancer patients.
Photo: Anja Aucamp

The field of Nuclear Medicine in South Africa and the rest of the world are expanding rapidly due to the development of hybrid cameras and new radiopharmaceuticals. These developments have a huge impact on the diagnosis and therapy of cancer.

The most advanced of these cameras, Positron emission tomography combined with normal CTs (PETCT), are not yet widely available in South Africa due to the cost of the cameras and the radiopharmaceuticals. A more cost-effective alternative can be of great benefit. To achieve this, the focus should be on developing new radiopharmaceuticals that can be used with the current cost-effective gamma cameras, according to University of the Free State researcher, Dr Je’nine Horn-Lodewyk from the Department of Nuclear Medicine.

Fluorodeoxyglucose (18F-FDG), a radiolabelled glucose analogue, is currently the radiopharmaceutical most commonly used in PET/CT imaging for mainly oncology indications. Although it is considered the gold standard for imaging in several malignancies, it does have certain disadvantages. An 18F-FDG PET/CT diagnostic imaging study can cost between R25 000 and R35 000 for a single patient in the private sector. The 18F-FDG is also more radioactive, which requires much stricter handling and shielding to avoid high radiation dosages to staff and patients.

Successful research potential innovative solution
In the search for the ideal radiopharmaceutical for tumour detection, the South African National Nuclear Energy Corporation (Necsa) developed a local synthesis process for ethylenedicysteine-deoxyglucose (EC-DG). EC-DG is also a glucose analogue similar to FDG. They succeeded in labelling the compound with Technetium-99-metastable-pertechnetate (99mTcO4-), the most common nuclear medicine isotope used for approximately 95% of nuclear medicine procedures, creating 99mTc-EC-DG.

In partnership with Dr Horn-Lodewyk, this compound was successfully used in various animal models and clinical scenarios, resulting in approval by the Medicine Control Council to use it in a human study. Research is also planned in order to investigate diagnostic accuracy in other cancers like lymphoma.  The end result of this research can produce a radiopharmaceutical that is cost effective, does not require the use of costly specialised equipment, has no significant side-effects, no special patient preparation, renders late imaging possible, and has decreased radiation risks.

Dr Horn-Lodewyk is grateful for the support of her mentor, Prof Anton Otto, as well as Dr Gert Engelbrecht, Head of the Department of Nuclear Medicine, Prof Jan Rijn Zeevaart from North-West University’s Preclinical Drug Development Platform and Necsa, and Judith Wagener from Necsa. This innovative research would also not have been possible without the financial assistance of Dr Glen Taylor and Eleanor van der Westhuizen in the Directorate of Research Development.

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept